Daniel Pfeffer, PhD
Senior Data Science Manager
Expertise:
Daniel has a background in cosmology where he developed tools to apply machine learning techniques to the field.
At EVERSANA, he has worked extensively with medical insurance claims and electronic health records (EHR) on many types of analysis. These analysis include describing and visualizing patient journeys through the healthcare system for different diseases, building machine learning models to find undiagnosed patients with rare diseases and determine predictors of these diseases, and determining the cost of care and healthcare utilization of patients.
Daniel has also improved EVERSANA’s ability to run analytics by actively updating and improving their internal analysis tools.
Articles by Daniel Pfeffer, PhD
Association between Targeted Therapy and Survival in Patients with Myelodysplastic Syndromes
Precision oncology offers a new approach to cancer care by providing targeted treatments for patients with actionable genetic mutations. However, in the U.S., nearly one-third of eligible patients face barriers such as delayed test results, limited awareness and access issues, impacting survival outcomes. Pierantonio Russo, MD, Ramaa Nathan, PhD, Daniel Pfeffer, PhD, and Alex Moore, PhD, conducted a study that highlights the potential of targeted therapies for patients with myelodysplastic syndromes (MDS), a challenging hematologic malignancy. By analyzing genomic and claims data from over 3,600 patients, the research demonstrates a 46.5% reduction in 12-month mortality rates among patients receiving targeted therapies compared to those who did not. Remarkably, therapies like […]
Association Between Targeted Therapy and Survival in Patients With Acute Myeloid Leukemia
Precision oncology innovatively addresses cancer care by targeting treatments to patients with specific biomarker alterations. However, in the U.S., nearly one-third of eligible patients miss out on these life-saving therapies. Operational barriers, physician awareness gaps, slow test result turnaround times (TATs) and reimbursement challenges create significant obstacles, leaving many without treatments that could dramatically improve their chances of living longer. For acute myeloid leukemia (AML)—a blood cancer with a poor prognosis—these disparities are especially dire. High-risk patients face limited options, but even without complete remission, targeted therapies can extend their lives. In a study conducted by Pierantonio Russo, MD, Ramaa Nathan, PhD, Daniel Pfeffer, PhD, and Alex Moore, PhD, they […]